InvestorsHub Logo
Followers 10
Posts 1456
Boards Moderated 0
Alias Born 08/02/2010

Re: Altitrade Partners post# 6696

Thursday, 11/01/2018 12:08:50 PM

Thursday, November 01, 2018 12:08:50 PM

Post# of 11429

Agree with your post.

Of course, the Q3 results won't "deodorize" the hype, because the hype could not possibly show results in Q3, and minimal in Q4.

But there are plenty of scenarios in the results and conference call that may well be bullish:

1) Growth in the non-CBD product lines
2) Reiteration that Q4 will be profitable
3) Positive reception/launch of Enhaced Recovery line
4) Characterization of CBD partnerships, initial sales, projected ramp, etc.

They already announced 110,000 points of distribution for CBD. If this ramp were to start in March, using average beverage sell through, this would add $21M to 2019 sales. But if the reception were a reasonable expectation 50% greater than average, ad they sign deals to double the points of distribution to 220,000, then you're talking adding $63M to 2019 revenue. One could argue that those incremental sales, over time, would add the current market cap to the market cap.

Another reasonable bet is that Wilis will not be shy about his optimism. The question will be what actual names and numbers he shares.